Study finds almost 1 in 3 large clinical trials still not published 5 years after completion
Almost one in three (29%) large clinical trials remain unpublished five years after completion. And of these, 78% have no results publicly available, finds a study published on bmj.com today.
This means that an estimated 250,000 people have been exposed to the risks of trial participation without the societal benefits that accompany the dissemination of their results, say the authors.
They argue that this “violates an ethical obligation that investigators have towards study participants” and call for additional safeguards “to ensure timely public dissemination of trial data.”
Randomized clinical trials are a critical means of advancing medical knowledge. They depend on the willingness of people to expose themselves to risks, but the ethical justification for these risks is that society will eventually benefit from the knowledge gained from the trial.
But when trial data remain unpublished, the societal benefit that may have motivated someone to enrol in a study remains unrealized.
US law requires that many trials involving human participants be registered – and their results posted – on the largest clinical trial website ClinicalTrials.gov. But evidence suggests that this legislation has been largely ignored.
So a team of US-based researchers set out to estimate the frequency of non-publication of trial results and, among unpublished studies, the frequency with which results are unavailable in the ClinicalTrials.gov database.
They searched scientific literature databases and identified 585 trials with at least 500 participants that were registered with ClinicalTrials.gov and completed prior to January 2009. The average time between study completion and the final literature search (November 2012) was 60 months for unpublished trials.
Registry entries for unpublished trials were then reviewed to determine whether results for these studies were available in the ClinicalTrials.gov results database.
Of 585 registered trials, 171 (29%) remained unpublished. Of these, 133 (78%) had no results available in ClinicalTrials.gov. Non-publication was more common among trials that received industry funding (32%) than those that did not (18%).
“Our results add to existing work by showing that non-publication is an important problem even among large randomized trials,” say the authors. Furthermore, the sponsors and investigators of these unpublished trials infrequently utilize the ClinicalTrials.gov results database.
Go deeper with Bing News on:
- Gaithersburg biotech company is entering phase on of clinical trials for COVID-19 vaccineon May 13, 2020 at 3:52 pm
According to the Mayo Clinic a vaccine to prevent COVID-19 is the best hope for ending the pandemic. Could the answer be in our backyard?
- Stem Cells | Worldwide Pipeline Landscape Assessment 2020: Clinical Trial Stages, Drug Mechanism Classes, Companies Involvedon May 13, 2020 at 3:30 pm
PRNewswire/ -- The "Stem Cells Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering. This research report provides the ...
- BRIEF-Immunic Receives First Regulatory Approval From German Health Authority BfArM To Initiate Phase 2 Clinical Trial Of IMU-838 In COVID-19 Patientson May 13, 2020 at 1:57 pm
RECEIVES FIRST REGULATORY APPROVAL FROM GERMAN HEALTH AUTHORITY BFARM TO INITIATE A PHASE 2 CLINICAL TRIAL OF ITS SELECTIVE ORAL DHODH INHIBITOR, IMU-838, IN COVID-19 PATIENTS * IMMUNIC INC - DOSING ...
- RDIF and ChemRar Announce First Interim Results of Clinical Trials of Favipiravir Drug's Effectiveness in Coronavirus Therapyon May 13, 2020 at 12:15 pm
Russia's sovereign wealth fund, and the ChemRar Group today announce the positive first interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on ...
- UCI to take part in clinical trial of drug for critically ill COVID-19 patientson May 13, 2020 at 11:39 am
UCI Health will initiate a clinical study of a drug to treat critically ill COVID-19 patients who face a high mortality rate because of acute inflammation that fills their lungs with fluid, a grave ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
Unpublished trial data
- Head to Head: Is Chloroquine or Remdesivir the Drug to Treat Coronavirus?on May 11, 2020 at 11:22 pm
Remdesivir is being endorsed by Donald Trump’s scientific adviser, Anthony Fauci. Fauci claimed that Raoult’s treatment may have “no effect”, and Raoult returned the favour by accusing Fauci’s trial ...
- Coronavirus: scientists promoting chloroquine and remdesivir are acting like sports rivalson May 11, 2020 at 7:30 am
Rivals Usain Bolt and Justin Gatlin trash-talked each other before the 2016 Olympics, with Bolt calling Gatlin “old man”, and Gatlin calling Bolt “middle aged”. The banter was entertaining but ...
- Markman Biologics Will Revolutionize the Wound Care Domainon May 6, 2020 at 1:00 pm
Markman Biologics Corporation is a first mover in the wound care domain. Markman Biologics, a Nevada Corporation Corporation, is ...
- Experts Say an Antiviral Drug Shows “Clear-Cut” Promise as a COVID-19 Treatmenton May 2, 2020 at 2:25 pm
The antiviral drug remdesivir has been granted emergency use authorization to treat severely ill COVID-19 patients, the FDA has announced. Anthony Fauci, M.D., head of the National Institutes of ...
- Conflicting Data on Remdesivir for Covid-19 Highlight Efficacy Questionson May 1, 2020 at 2:53 am
Despite conflicting data on the efficacy of the investigational drug remdesivir for the treatment of SARS-CoV-2, federal officials and the nation’s top infectious disease doctor enthusiastically ...